Literature DB >> 16328603

Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies.

D Villalta1, N Bizzaro, S Platzgummer, A Antico, M Tampoia, L Camogliano, D Bassetti, M Pradella, A Piazza, F Manoni, R Tozzoli, E Tonutti.   

Abstract

Reports of a possible correlation between anti-Scl-70 antibody concentration and clinical manifestations in systemic sclerosis patients have recently appeared in the scientific literature. The goal of our study was to evaluate, by means of a multicenter study, the analytical reliability of immunoassay systems in the quantitative measurement of Scl-70 antibodies. Three blind samples (H, M, L) at different anti-Scl-70 antibody concentrations, and a low concentration antibody serum (LPC) used as a common calibrator, were sent three times in a 6-month time span to 39 Italian clinical laboratories. Each laboratory was asked to calculate dosages following the enzyme-linked immunosorbent assay (ELISA) method they used and report the optical density values of each sample (ODs), of the cutoff serum provided by the manufacturer of the kit used (ODco) and of LPC (ODLPC). The overall analytical imprecision (between methods and between laboratories) of the three different determinations of the values respectively expressed in ODs, ODs/ODco and ODs/ODLPCratio was 47.1, 52.8 and 34.0% for sample H, 56.2, 47.4% and 34% for sample M and 84.6, 86.0 and 86.6% for sample L. The average intra-method analytical imprecision was, respectively, 20.7, 29.8 and 18.6% for sample H, 24.6, 26.5 and 19.3% for sample M, and 30.6, 28.1 and 20.2% for sample L. The commercial ELISA methods currently used to determine the presence of anti-Scl-70 autoantibodies show considerable differences in the quantitative determination. The best results for reproducibility analyses have been obtained when the values were expressed as a ratio between the ODs of the sample and of the common calibrator (ODs/ODLPC). Forward-looking clinical studies that can clarify the usefulness of quantitative determination of anti-Scl-70 antibodies in the monitoring of diffuse scleroderma patients can be performed only when standard serum with a known antibody concentration and calibration curves for quantitative ELISA measurements are made available.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16328603     DOI: 10.1007/s10067-004-1054-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  41 in total

1.  A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content.

Authors:  Eng M Tan; Josef S Smolen; J Steven McDougal; Marvin J Fritzler; Thomas Gordon; John A Hardin; Joachim R Kalden; Robert G Lahita; Ravinder N Maini; Westley H Reeves; Naomi F Rothfield; Yoshinari Takasaki; Allan Wiik; Merlin Wilson; James A Koziol
Journal:  J Rheumatol       Date:  2002-01       Impact factor: 4.666

2.  Use of recombinant RNP peptides 70K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients.

Authors:  D J de Rooij; W J Habets; L B van de Putte; M H Hoet; A L Verbeek; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

3.  Immunologic factors and clinical activity in systemic lupus erythematosus.

Authors:  P H Schur; J Sandson
Journal:  N Engl J Med       Date:  1968-03-07       Impact factor: 91.245

4.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis.

Authors:  V D Steen; D L Powell; T A Medsger
Journal:  Arthritis Rheum       Date:  1988-02

5.  Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block.

Authors:  M Reichlin; A Brucato; M B Frank; P J Maddison; V R McCubbin; M Wolfson-Reichlin; L A Lee
Journal:  Arthritis Rheum       Date:  1994-11

Review 6.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

7.  Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus.

Authors:  D A Isenberg; Y Shoenfeld; R S Schwartz
Journal:  Arthritis Rheum       Date:  1984-02

8.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  IgG and IgM anti-snRNP reactivity in sequentially obtained serum samples from patients with connective tissue diseases.

Authors:  U Nyman; I Lundberg; E Hedfors; M Wahren; I Pettersson
Journal:  Ann Rheum Dis       Date:  1992-12       Impact factor: 19.103

10.  Detection of autoantibodies in a quantitative immunoassay using recombinant ribonucleoprotein antigens.

Authors:  W J Habets; M H Hoet; P T Sillekens; D J De Rooij; L B Van de Putte; W J Van Venrooij
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

View more
  2 in total

1.  Fever of unknown origin secondary to type I crescentic glomerulonephritis and anti-SCl 70 antibodies without clinical manifestations of systemic sclerosis.

Authors:  Jorge Vega Stieb; Helmuth Goecke Saavedra; Gonzalo Méndez Olivieri
Journal:  Clin Exp Nephrol       Date:  2008-05-20       Impact factor: 2.801

Review 2.  Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!

Authors:  Allan S Wiik; Nicola Bizzaro
Journal:  Auto Immun Highlights       Date:  2012-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.